大剂量支气管动脉灌注化疗栓塞与全身静脉化疗治疗晚期非小细胞肺癌疗效的对比研究-现代医学

大剂量支气管动脉灌注化疗栓塞与全身静脉化疗治疗晚期非小细胞肺癌疗效的对比研究

单位：天长市中医院肿瘤科, 安徽天长 239300

分类号：R734.2

出版年·卷·期（页码）：2023·51·第二期（216-219）

摘要：

目的：比较大剂量支气管动脉灌注化疗栓塞和全身静脉化疗治疗晚期非小细胞肺癌的临床疗效。方法：选择2015年6月至2019年6月我院收治的接受支气管动脉化疗栓塞术或全身静脉化疗的肺癌患者115例，其中支气管动脉化疗栓塞组55例（试验组），全身静脉化疗组60例（对照组），观察比较两组肿瘤局部控制/缓解率、并发症、生活质量及生存时间。结果：接受支气管动脉化疗栓塞术的患者中位生存时间为567 d，接受全身静脉化疗的患者中位生存时间为544 d （P=0.951）。试验组和对照组的肿瘤控制率分别为80.1％和78.3％（P=0.196），肿瘤缓解率分别为70.9%和51.7%（P=0.035），严重并发症发生率分别为4.0%和15.0%（P=0.038）。两组患者术后生活质量均显著提高（P<0.001）。结论：对于晚期不可切除的非小细胞肺癌患者，大剂量支气管动脉灌注化疗栓塞治疗可以提高肿瘤局部缓解率，降低严重并发症发生率，提高患者生活质量。

Objective: To compare the effect of high-dose bronchial arterial infusion chemotherapy with that of systemic intravenous chemotherapy on the treatment of advanced non-small cell lung cancer(NSCLC). Methods: From June 2015 to June 2019, a total of 115 patients with unresectable NSCLC received high-dose bronchial arterial infusion chemotherapy or systemic intravenous chemotherapy in our hospital, of whom 55 patients were treated with high-dose bronchial arterial infusion chemotherapy group(experimental group) and 60 with systemic intravenous chemotherapy(control group). The overall survival time, complications, local tumor control or remission rate and life quality of the patients were studied and compared between the two groups. Results: The median overall survival time in the experimental group and the control group was 567 days and 544 days(P=0.951), respectively. The local tumor control rates were 80.1% and 78.3%(P=0.196), and the local tumor remission rates were 70.9% and 51.7% in the two groups, respectively. The incidence of severe complications was 4% and 15.0%(P=0.038). Patients' quality of life was significantly improved in the two groups(P<0.001). Conclusion: For patients with advanced NSCLC, the treatment strategy of high-dose bronchial arterial infusion chemotherapy may provide a better local tumor response rate, reduce the incidence of chemotherapy related complications, and improve the patients' quality of life.

参考文献：

[1] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al.Estimating the global cancer incidence and mortality in 2018:Globocan sources and methods[J].Int J Cancer, 2019, 144(8):1941-1953.
[2] SIEGEL R L, MILLER K D, JEMAL A.Cancer statistics, 2020[J].CA Cancer J Clin, 2020, 70(1):7-30.
[3] Chinese Association for Clinical Oncologists[clinical practice guideline for stage primary lung cancer in china(2020 version)] [J].Zhonghua Zhong Liu Za Zhi, 2020, 42(1):1-16.
[4] HANNA N H, SCHNEIDER B J, TEMIN S, e t al.Therapy for stage iv non-small-cell lung cancer without driver alterations:Asco and oh(cco) joint guideline update[J].J Clin Oncol, 2021, 39(9):1040-1091.
[5] ZHU J, ZHANG H P, JIANG S, et al.Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage Ⅲ squamous cell lung cancer[J].Ther Adv Respir Dis, 2017, 11(8):301-309.
[6] FU Y F, LI Y, WEI N, et al.Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer:Long-term outcome and predictor of survival[J].Radiol Med, 2016, 121(7):605-610.
[7] NAKANISHI M, UMEDA Y, DEMURA Y, et al.Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients:four clinical specified cases[J].Lung Cancer, 2007, 55(2):241-247.
[8] CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2):115-132.
[9] BARNES D J.Bronchial arterial infusion for lung cancer[J].Chest, 2000, 117(5):1525.
[10] YAN D, ZHOU C W, LIU D Z, et al.Evaluation of the efficacy of bronchial arterial infusion chemotherapy for the treatment of central non-small cell lung cancer[J].Zhonghua Zhong Liu Za Zhi, 2011, 33(4):302-304.
[11] HUANG X, YU C, WANG L, et al.A radomized trial of bronchial arterial infusion(BAI), traditional vein chemotherapy and BAI plus vein chemotherapy sequential therapy in the treatment of advanced and late NSCLC[J].Zhongguo Fei Ai Za Zhi, 2008, 11(2):260-263.
[12] ALHARBI A F, KRATZKE R A, D'CUNHA J, et al.Gemcitabine and metabolite pharmacokinetics in advanced nsclc patients after bronchial artery infusion and intravenous infusion[J].Cancer Chemother Pharmacol, 2019, 83(2):387-391.
[13] BIE Z, LI Y, LI B, et al.The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer[J].Thorac Cancer, 2019, 10(9):1770-1778.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录